Juzimette

Metformin Hydrochloride and Sitagliptin, the active ingredient in Juzimette, is a biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control.

GNH USA supplies Juzimette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juzimette is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Inadequate control on metformin alone: provides additional glucose‑lowering effect when added to existing therapy. - Combination therapy with other antidiabetics: enhances overall glycaemic management while allowing dose reduction of individual agents.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with insulin or sulfonylureas. - Metallic taste: transient alteration in taste perception. - Weight neutrality: no significant change in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Acute pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycaemia: prolonged low blood glucose requiring assistance. - Allergic reactions: rash, pruritus, or angio‑edema. - Hepatic dysfunction: elevated transaminases or liver injury. - Renal impairment: worsening kidney function, especially with metformin accumulation.

Before prescribing Juzimette, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. - Hepatic disease: contraindicated in patients with significant liver dysfunction. - Risk of lactic acidosis: discontinue if symptoms of acidosis develop. - Pregnancy and lactation: use only if potential benefit justifies risk. - Drug interaction review: assess concomitant medications that may affect clearance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Juzimette may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase sitagliptin plasma concentrations. - Iodinated contrast agents with metformin: heightened risk of renal dysfunction and lactic acidosis. - Concurrent insulin secretagogues: increased risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal clearance of metformin, necessitating dose adjustment. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Beta‑blockers: may mask hypoglycaemia symptoms, requiring patient education.